Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 27, 2023

Details for Patent: 8,022,082

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,022,082 protect, and when does it expire?

Patent 8,022,082 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in thirty countries.

Summary for Patent: 8,022,082
Title:Method for the administration of an anticholinergic by inhalation
Abstract: An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 {square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 .mu.m, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 .mu.m to 500 .mu.m, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 {square root over (kPa)} min/L containing the inhalable powder.
Inventor(s): Zierenberg; Bernd (Bingen am Rhein, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim am Rhein, DE)
Application Number:11/427,173
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery; Device;

Drugs Protected by US Patent 8,022,082

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,022,082

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02007868Apr 09, 2002
02007868Apr 9, 2002

International Family Members for US Patent 8,022,082

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039276 See Plans and Pricing
Australia 2003226775 See Plans and Pricing
Australia 2009200716 See Plans and Pricing
Brazil 0309117 See Plans and Pricing
Canada 2481876 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.